ATRC insider trade: 5,166 AtriCure shares sold, 78,798 held

Rhea-AI Filing Summary

AtriCure, Inc. (ATRC) reported an insider stock transaction by its Chief Marketing & Strategy Officer. On 11/26/2025, the officer sold 5,166 shares of AtriCure common stock in an open market transaction coded "S" for sale.

The reported sale price is a weighted average of $37.29 per share, with individual trades executed at prices ranging from $36.51 to $38.44 per share. After this transaction, the officer beneficially owns 78,798 shares of AtriCure common stock, held directly.

Insider Trade Summary

Net Seller: 5,166 shares ($192,640)

Net Sell 1 txn

Insider Noznesky Justin J

Role Chief Mktg & Strategy Officer

Sold 5,166 shs ($193K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,166	$37.29	$193K

Holdings After Transaction: Common Stock — 78,798 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Noznesky Justin J

(Last) (First) (Middle)

7555 INNOVATION WAY

(Street)

MASON OH 45040-9695

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Mktg & Strategy Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/26/2025		S		5,166	D	$37.29(1)	78,798	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $36.51 to $38.44 per share. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ Justin J. Noznesky	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AtriCure (ATRC) report in this Form 4?

The Chief Marketing & Strategy Officer of AtriCure (ATRC) reported the sale of 5,166 shares of AtriCure common stock in an open market transaction.

At what price were the AtriCure (ATRC) shares sold in this Form 4?

The reported sale price was a weighted average of $37.29 per share, with individual trades executed between $36.51 and $38.44 per share.

When did the AtriCure (ATRC) insider sale take place?

The insider sale of AtriCure common stock occurred on 11/26/2025.

How many AtriCure (ATRC) shares does the insider own after the sale?

Following the reported transaction, the officer beneficially owns 78,798 shares of AtriCure common stock, held directly.

Who is the reporting person in this AtriCure (ATRC) Form 4?

The reporting person is an AtriCure officer serving as Chief Marketing & Strategy Officer.

Does this AtriCure (ATRC) Form 4 involve any derivative securities?

The filing’s derivative securities table does not report any specific derivative transactions; the reported activity involves common stock only.